TICKERNERD
Menu
NBIXNBIXHealthcare · Drug Manufacturers - Specialty & Generic

NBIX Stock Forecast: Neurocrine Biosciences, Inc. Price Predictions for 2026-2027

Last close, 27 Oct 2026
$146
+0.09% on the day

The 29 Wall Street analysts covering Neurocrine Biosciences, Inc. hold a median 12-month price target of $212 — +44.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 86 of 100 as at 27 Oct 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$14.8B
Ticker Nerd rank
86/ 100
Median analyst target
$212
Analysts covering
29
Revenue$959.0M+39.5% y/y
Operating income$153.0M
Net income$144.4M
Free cash flow$128.6M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+2.8%
1M
+5.5%
YTD
+2.9%
1Y
−2.0%
From 52W high
−21.3%
From 52W low
+18.6%
$123
$186
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

NBIX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Neurocrine Biosciences, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 27 Oct 2026
86/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value
98
Quality
97
Volatility
95
Growth
92
Issuance
74
Momentum
58
Revisions
58
Accruals
31
Size
12

Value (98): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Accruals (31): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Size (12): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

NBIX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on NBIX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$100$150$200$250Jan 26Apr 26Jul 26Oct 26NBIXHigh $253Median $212Low $150

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says29 analysts
25 Buy4 Hold0 Sell
Low $150Median $212High $253

The green dot is the last close — the median target sits +44.9% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 6 moved their price target up and 3 moved it down.

DateFirmActionRatingTarget
16 Oct 2026NeedhamReiteratesBuy$204
12 Oct 2026BMO CapitalMaintainsMarket Perform$164 → $150
6 Oct 2026GuggenheimAssumesBuy$207
29 Sept 2026UBSMaintainsBuy$231 → $214
29 Sept 2026UBSMaintainsBuy—
11 Sept 2026Morgan StanleyMaintainsEqual-Weight$182 → $183
11 Sept 2026Morgan StanleyMaintainsEqual-Weight—
8 Sept 2026RBC CapitalReiteratesOutperform$198
8 Sept 2026RBC CapitalReiteratesOutperform—
3 Sept 2026CitigroupMaintainsBuy—
3 Sept 2026CitigroupMaintainsBuy$249 → $253
13 Aug 2026Morgan StanleyMaintainsEqual-Weight$196 → $182
13 Aug 2026Morgan StanleyMaintainsEqual-Weight—
3 Aug 2026Canaccord GenuityMaintainsBuy—
3 Aug 2026Canaccord GenuityMaintainsBuy$200 → $210
3 Aug 2026Truist SecuritiesMaintainsBuy$200 → $213
3 Aug 2026Truist SecuritiesMaintainsBuy—
3 Aug 2026WedbushMaintainsOutperform—
3 Aug 2026WedbushMaintainsOutperform$185 → $194
31 July 2026Cantor FitzgeraldMaintainsOverweight$210 → $215

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

NBIX appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.

Free. Unsubscribe any time.

Performance

NBIX vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 27 Oct 2026, Neurocrine Biosciences, Inc. returned −2.0% against +13.5% for the S&P 500, dividends included.

NBIX vs S&P 500, last 12 monthsTotal return, rebased to 100
8090100110120Jan 26Apr 26Jul 26Oct 26NBIXS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

NBIX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+3.2%
Analysts raising
1
Analysts cutting
1
Fundamentals

Neurocrine Biosciences, Inc. (NBIX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
21.4×

Cheaper than 35% of US stocks

Price / sales
4.4×

Cheaper than 26% of US stocks

Price / book
4.0×

Cheaper than 23% of US stocks

EV / EBITDA
16.3×

Cheaper than 20% of US stocks

Growth & margins
Revenue growth (YoY)
39.5%

Higher than 83% of US stocks

Earnings growth (YoY)
34.3%

Higher than 68% of US stocks

Gross margin
97.6%

Higher than 99% of US stocks

Operating margin
22.2%

Higher than 81% of US stocks

Net margin
20.9%

Higher than 83% of US stocks

Returns & dividend
Return on equity
22.1%

Higher than 83% of US stocks

Return on assets
11.7%

Higher than 94% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Neurocrine Biosciences, Inc. (NBIX) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Neurocrine Biosciences, Inc. has a market value of $14.8B and an enterprise value of $14.9B.

  • Revenue in the twelve months to 30 June 2026: $3.4B. The latest quarter grew 39.5% year on year.

  • Net income over the same four quarters: $705.5M, a 20.9% net margin.

  • Diluted earnings per share, trailing twelve months: $6.82.

  • Free cash flow in the twelve months to 30 June 2026: $870.4M, after $27.7M of capital spending.

  • Neurocrine Biosciences, Inc. spent $66.0M on share buybacks in the twelve months to 30 June 2026.

  • Shares outstanding: 101.6M.

  • Trailing P/E: 21.4×; forward P/E: 12.2× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Neurocrine Biosciences, Inc. employs 2,500 people — $1.3M of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 28 Oct 2026

Data provided by Twelve Data

Peers

NBIX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - Specialty & Generic
CompanyMarket capTKN rank
NBIXNeurocrine Biosciences, Inc.$14.8B86
ELANElanco Animal Health, Inc.$11.3B97
VTRSViatris, Inc.$21.6B99
UTHRUnited Therapeutics Corp.$25.1B81
ALKSAlkermes Plc$7.3B64
KNSAKiniksa Pharmaceuticals International Plc$6.9B98
AMRXAmneal Pharmaceuticals, Inc.$6.7B89

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Neurocrine Biosciences, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest NBIX news & analysis

Neurocrine Biosciences (NBIX) Earnings Expected to Grow: Should You Buy?

Zacks Investment Research · 26 Oct 2026negative

Zacks Investment Research says Neurocrine Biosciences lacks the combination of two key ingredients it views as indicating a likely earnings beat in the upcoming report. The headline frames the item around expected earnings growth and whether investors should buy.

Why it matters — NBIX watchers may note Zacks' caution about indicators for an earnings beat ahead of the company's upcoming report.

Neurocrine Biosciences Presents New Analysis Establishing Benchmark for Clinically Meaningful Change in Overall Health Reported by Patients with Tardive Dyskinesia

PRNewsWire · 26 Oct 2026positive

Neurocrine Biosciences announced an analysis establishing a 6-point increase on the EQ Visual Analogue Scale as a threshold for clinically meaningful improvement in overall health ratings among patients with tardive dyskinesia treated with INGREZZA. In KINECT-PRO, patients showed a mean 13.1-point improvement; the findings will be presented at AMCP Nexus 2026.

Why it matters — The analysis provides context for interpreting patient-reported health improvements associated with INGREZZA and adds to the research Neurocrine plans to present at the conference.

Where Will Neurocrine Biosciences Be in 5 Years?

The Motley Fool · 25 Oct 2026neutral

The Motley Fool’s article considers Neurocrine Biosciences’ outlook over the next five years, noting that Ingrezza sales are growing 15% and that two late-stage drug candidates have important clinical milestones in 2027.

Why it matters — NBIX watchers may want to track Ingrezza’s continued growth and the 2027 milestones for the company’s late-stage candidates.

Neurocrine Biosciences Announces Publication in Orphanet Journal of Rare Diseases Advancing Understanding of Hyperphagia in Prader-Willi Syndrome

PRNewsWire · 22 Oct 2026positive

Neurocrine Biosciences announced publication of expert perspectives in Orphanet Journal of Rare Diseases describing hyperphagia in Prader-Willi syndrome as a complex, neurobiologically driven condition. The authors emphasize multidimensional assessment and integrated care across patients’ lifespans, and identify VYKAT® XR as a treatment advance that may complement behavioral and environmental approaches.

Why it matters — The publication highlights Neurocrine’s VYKAT® XR and its relevance to treatment discussions for hyperphagia in Prader-Willi syndrome.

Neurocrine Biosciences Initiates Phase 2 Clinical Study Evaluating NBI-'567 in Adults with Alzheimer's Disease

PRNewsWire · 20 Oct 2026positive

Neurocrine Biosciences announced the initiation of a Phase 2 study of investigational NBI-1117567 (NBI-'567) in adults with mild to moderate Alzheimer's disease. The orally administered M1/M4, M1-preferring selective muscarinic agonist is being evaluated as an adjunctive treatment for cognitive impairment.

Why it matters — The study adds a clinical development update for NBIX's investigational Alzheimer's disease treatment program.

FAQ

Frequently asked questions about NBIX stock

What is the NBIX stock price forecast for 2026-2027?

The 29 Wall Street analysts covering Neurocrine Biosciences, Inc. have a median 12-month price target of $212, with estimates ranging from $150 to $253. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is NBIX stock a buy right now?

Of the 29 analysts covering Neurocrine Biosciences, Inc., 25 rate it a Buy, 4 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Neurocrine Biosciences, Inc. 86 out of 100 across roughly 4,600 US stocks as at 27 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank NBIX?

As at 27 Oct 2026, Neurocrine Biosciences, Inc. ranks 86 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (98 of 100).

Will NBIX stock go up?

No one can know that. What the data says: the median 12-month target from 29 analysts implies +44.9% from the last close, and Ticker Nerd's factor model ranks Neurocrine Biosciences, Inc. 86 out of 100 as at 27 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the NBIX stock forecast for 2030?

No analyst covering Neurocrine Biosciences, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for NBIX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $150 to $253 over the next 12 months.

How has NBIX stock performed over the past year?

Neurocrine Biosciences, Inc. returned -2.0% over the 12 months to 27 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Neurocrine Biosciences, Inc. do?

Neurocrine Biosciences, Inc. is a neuroscience-focused biopharmaceutical company that discovers, develops, and commercializes medicines for neurological, neuroendocrine, and neuropsychiatric disorders.

What is the latest news on NBIX?

The most recent item we track (Zacks Investment Research, 26 Oct 2026): "Neurocrine Biosciences (NBIX) Earnings Expected to Grow: Should You Buy?". Zacks Investment Research says Neurocrine Biosciences lacks the combination of two key ingredients it views as indicating a likely earnings beat in the upcoming report. The headline frames the item around expected earnings growth and whether investors should buy.

Company

About Neurocrine Biosciences, Inc.

Neurocrine Biosciences, Inc. is a neuroscience-focused biopharmaceutical company that discovers, develops, and commercializes medicines for neurological, neuroendocrine, and neuropsychiatric disorders. Its current portfolio includes treatments for movement disorders such as tardive dyskinesia and Huntington’s disease chorea, as well as therapies for endocrine conditions including congenital adrenal hyperplasia, endometriosis, and uterine fibroids. The company also maintains a clinical-stage pipeline spanning additional neuroscience and endocrine targets, with research programs aimed at addressing underserved patient populations. Neurocrine Biosciences, Inc. plays an important role in specialty pharmaceuticals by combining marketed products with ongoing drug development across complex, chronic conditions that often require long-term management. Headquartered in San Diego, California, it serves patients and healthcare providers in the United States and internationally through its commercial operations and development activities.

CEO Mr. Kyle W. Gano Ph.D. · 2,500 employees · United States · https://www.neurocrine.com